JoannaYiMD

Pediatric Hematology & Oncology • Houston, TX

Assistant Professor, Pediatric Hematology/Oncology, Baylor College of Medicine/Texas Children’s Hospital

Join to view full profile

Dr. Yi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Yi's full profile

Already have an account?

Office
1102 Bates Ave
Ste 1220
Houston, TX 77030
Phone+1 832-822-4242

Education & Training

Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 2010 - 2013
University of MinnesotaResidency, Pediatrics, 2007 - 2010
University of Wisconsin School of Medicine & Public HealthClass of 2007

Certifications & Licensure

TX State Medical License 2015 - 2025
MA State Medical License 2010 - 2016
MN State Medical License 2008 - 2010
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Publications & Presentations

PubMed

MLL oncoprotein levels influence leukemia lineage identities.
Derek H Janssens, Melodie Duran, Dominik J Otto, Weifang Wu, Yiling Xu
Nature Communications. 2024-10-29
EZH2-driven immune evasion defines high-risk pediatric AML with t(16;21) FUS::ERG gene fusion.
Nathaniel J Buteyn, Connor G Burke, Vincent J Sartori, Eve Deering-Gardner, Zachary J DeBruine
Biorxiv. 2024-06-25
24 citations
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.
Susan N Chi, Joanna S Yi, P Mickey Williams, Sinchita Roy-Chowdhuri, David R Patton
Journal of the National Cancer Institute. 2023-11-08

Abstracts/Posters

An Oncogenic Enhancer Encodes Selective Selenium Dependency in AML
Joanna S. Yi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results fro...
Joanna S. Yi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Rara Is a Druggable Super-Enhancer Regulated Dependency in Pediatric AML
Joanna S. Yi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Pa...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

Novel Approach Identifies Highly Specific Anti-Cancer CompoundsJune 3rd, 2022
Researchers Discover Potential Achilles Heel of Pediatric Acute Myeloid LeukemiaSeptember 23rd, 2021